AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05389085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Reflectance confocal microscopy (RCM), Photoacoustic imaging (PAI) and tape-strippng of RNA and lipids
Description: In vivo RCM will be used to diagnose pigmented tumours at a cellular level and provide information on skin microarchitecture. MSOT detects skin chromophores as melanin, hemoglobin, water, collagen, and lipids, which will be included in analysis of diagnostic accuracies. MSOT will also be used to measure tumour thickness; delineate tumour borders and analyze blood flow in blood vessels. Potential diagnostic features from each lesion type will be tested. RNA and lipid profiles from tape stripping results will be compared to imaging and histopathology diagnosis.
Study NCT04714931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sentinel lymph node detection
Description: Tracer (Indocyanine green or blue dye) will be injected into the IP and utero-ovarian ligaments, after opening of the pelvic and paraaortic retroperitoneal spaces, sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.
Study NCT05240820 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: multi-layer wound closure
Description: We prospectively analyze clinical outcome data from 30 subjects who perform multi-layer wound closure using polyglactin 910 and polypropylene, and polydioxanone and combination of 2-octyl cyanoacrylate and polyester mesh following excision of giant benign tumors.
Study NCT05240820 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: multi-layer wound closure
Description: We prospectively analyze clinical outcome data from 30 subjects who perform multi-layer wound closure using polyglactin 910 and polypropylene, and polydioxanone and combination of 2-octyl cyanoacrylate and polyester mesh following excision of giant benign tumors.
Study NCT04546711 — intervention group
Intervention type: OTHER
Intervention: Ketogenic Diet
Description: The ketogenic diet (KD) is a high fat, very low carbohydrate diet
Study NCT01529892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A single oral 5 mg of duterium labeled methamphetamine
Study NCT06297369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N acetyl cysteine
Description: N-acetylcysteine 600 mg twice daily (acetylcystein ® 600 mg effervescent instant granules sachets, Sedico, Egypt)
Study NCT04992312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon Nasal Powder [Baqsimi]
Description: Administered intranasally
Study NCT04764071 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous nephrolithotomy
Description: percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 30F.
Study NCT04764071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultra-mini percutaneous nephrolithotomy
Description: percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 12-14 F fascial dilator was used to dilate the nephrostomy tract to pass the 13 F semi-rigid plastic sheath.
Study NCT05577507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholestyramine Resin 4000 MG [Questran]
Description: cholestyramine 4 gram sachets (questran) will be administered orally three times daily for 8 weeks period trial
Study NCT05577507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate 500 MG Oral Tablet
Description: control group will administer standard therapy calcimate 500 mg three times daily within meals
Study NCT05577507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate 500 MG Oral Tablet
Description: control group will administer standard therapy calcimate 500 mg three times daily within meals
Study NCT04552652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Remotely monitored exercises will be performed at home. The high-intensity interval group warms-up for 5 minutes at moderate intensity (65-75% of maximal heart rate). After warm-up exercise, will continue in 4 minutes intervals at high-intensity to reach the target zone (85-95% of maximal heart rate) Each interval will be separated by 3 minutes of active recoveries (at 65-75% of maximal heart rate). The session ends with a 3-minute cool-down phase. Overall training exercise time will be 33 minutes - isocaloric compared to moderate-intensity continous training group. All participants will train using a heart rate monitor during each workout.
Study NCT04552652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity continuous training
Description: Remotely monitored exercises will be performed at home. Patients in the moderate-intensity continuous training group will perform a 41-minute constant workout with an intensity of 65-75% of maximum heart rate, representing the same total training load as the high-intensity aerobic exercise group. All participants will train using a heart rate monitor during each workout.
Study NCT05121064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Brief Intervention
Description: The alcohol brief intervention (BI) was based on CETA'S substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring possibilities of change, goal setting, identifying reasons for alcohol use and skill building) including a 2-week alcohol timeline follow back assessment completed by provider. The alcohol brief intervention (BI) will be conducted by a trained counselor.
Study NCT05121064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach
Description: CETA is a multisession cognitive behavioral therapy (CBT)-based model. CETA consists of elements: engagement, safety assessment, psychoeducation, substance use reduction, behavioral activation, cognitive coping, relaxation, exposure and problem solving. During a weekly clinic meeting, newly enrolled participants who are assigned to get CETA will be assigned to a specific counselor. The counsellor, together with their supervisor, will design an individualized treatment plan including type and order of Common Elements Treatment Approach (CETA) for each participant. The counsellor will contact participants by phone or home visit to schedule CETA session. CETA sessions will begin with standardized clinical monitoring form to track progress of treatment and each session will last 45-90 minutes.
Study NCT05121064 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care (SOC) at HIV clinics in Zambia consist of Antiretroviral Treatment (ART) adherence counselling. All participants will receive Standard of Care (SOC), but for participants in Arm C it will be the only alcohol treatment. The ART adherence counseling includes brief unstructured discussion of substance use and mental health issues with a focus on issues that reduce adherence and retention issues. ART adherence counseling is delivered in a one-on-one format between patient and counsellor and it usually lasts 5-10 minutes.
Study NCT03787511 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cough assessment
Description: Cough assessment with cough visual analog scale (VAS), and Leicester Cough Questionnaire (LCQ) for Diabetic patients with chronic cough and Diabetic patients without chronic cough
Study NCT03787511 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurological tests and cardiovascular tests
Description: Neurological tests : electromyography, thermotest, QSAR + cardiovascular test for Diabetic patients with chronic cough and Diabetic patients without chronic cough
Study NCT03787511 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy to evaluate small fiber neuropathy for Diabetic patients with chronic cough and Diabetic patients without chronic cough
Study NCT05186194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D, Calcium
Description: Vitamin D, calcium are available in tablets. During the 8 weeks of training, subjects were asked to take supplement tablets per day after dinner.
Study NCT05186194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06372873 — intervention group
Intervention type: OTHER
Intervention: re-evaluate by two senior radiologists in our medical center
Description: The allocated images obtained from the contributing hospitals will be re-evaluated by two senior radiologists in our clinical center
Study NCT06243393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan (SG)
Description: Treatment with Sacituzumab Govitecan (SG)
Study NCT06243393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physicians Choice (PhC).
Description: Treatment according to oncologic guidelines.
Study NCT05773664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon
Description: Given PO
Study NCT05773664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of cavity fluid and blood samples
Study NCT05773664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of cavity fluid and blood samples
Study NCT05773664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05773664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05773664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT05773664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT05773664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging of the Brain with and without Contrast
Description: Undergo MRI with or without contrast
Study NCT05773664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging of the Brain with and without Contrast
Description: Undergo MRI with or without contrast
Study NCT05705934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Each session of the exercise program will last 50 minutes and will consist of 4 stages. At these stages, it is aimed to work the social, physical, spiritual and mental parameters of the holistic approach.
Study NCT05671146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anti-gravity treadmill
Description: participants will perform exercises with partial weight-bearing by using an anti-gravity treadmill
Study NCT05671146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight-bearing exercises for knee flexors and extensors
Description: Stretching and strengthening exercises will be performed in a weight-bearing position
Study NCT05671146 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non weight-bearing exercises for knee flexors and extensors
Description: Stretching and strengthening exercises will be performed in a non-weight-bearing position
Study NCT06300463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: 75 mg IV Q6W
Study NCT06300463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: 450 mg IV Q3W
Study NCT06300463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1423
Description: 30 mg/kg IV Q3W
Study NCT06300463 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 8Gy x 3 between Day 0 - 18; Allowed techniques for radiation are 3D conformal, intensity modulated radiotherapy (IMRT), or SBRT
Study NCT05068297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incrediwear Germanium-Embedded Knee Brace following ACL reconstruction
Description: Germanium-Embedded Knee Brace will be applied to the effected limb following ACL reconstruction
Study NCT05068297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Replica Knee Brace
Description: Replica Knee brace will be applied to the effected limb following ACL reconstruction
Study NCT05438862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: State of art aortic valve surgery
Description: Optimal surgical treatment (aortic valve-sparing surgery, aortic valve replacement, Ross procedure).
Study NCT05444153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive 1 tablet of oral semaglutide once daily.
Study NCT05444153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Participants will receive 1 tablet of empagliflozin once daily.
Study NCT06271629 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Insomnia severity index
Description: The ISI score is a self-report questionnaire consisting of 7 items designed to assess the nature, severity, and impact of insomnia.(16) The typical recall period for respondents is the last month. The evaluated dimensions include the severity of sleep onset, sleep maintenance, and early morning awakening problems, as well as sleep dissatisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems by others, and the distress caused by the sleep difficulties.
Study NCT04953325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 Vaccine
Description: 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
Study NCT04953325 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: 25μg each of the following serotypes/each dose (0.5ml): 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
Study NCT04953325 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Inactivated Hepatitis A Vaccine
Description: 500SU inactivated Hepatitis A virus in 1 mL of aluminium hydroxide solution per injection.
Study NCT04975477 — intervention group
Intervention type: PROCEDURE
Intervention: Esophagogasrtoduodendoscopy and liver stiffness
Description: Time frame between elastography measurement and esophagogastroduodendoscopy is within 6 months.
Study NCT04975477 — intervention group
Intervention type: PROCEDURE
Intervention: hepatic venous pressure gradient
Description: A method was used to evaluate portal pressure.
Study NCT05577884 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: noncontrast-enhanced whole-body CT
Description: noncontrast-enhanced low-dose whole-body CT using dual-source CT scanner using A-tube (75% radiation) and B-tube (25% radiation).~* conventional low-dose CT data (A +B tubes, 100% dose) are reconstructed with iterative reconstruction~* ultra-low dose CT data (B-tube only, 25% dose) are reconstructed with deep learning commercially available software.
Study NCT05566977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous adoptive T regulatory cell transfer.
Description: Identification and count, using flowcytometry, for human Tregs will be based on both positive and negative cell markers, human Tregs are (CD4+, CD25+, CD127-, Foxp3+). Peripheral heparinized venous blood will be used .GMP-Compliant Protocol for the Isolation and Expansion of Tregs for Clinical Application .Cryopreservation of Expanded Tregs .Administration of T reg cells and follow-up of adverse events.
Study NCT05273697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Underwater Cold Snare Polypectomy
Description: The procedure of Underwater Cold Snare Polypectomy (UP) will be as follows:~1. Complete suction of air from the intestinal tract~2. Partial opening of the intestinal lumen by using sterile room temperature water via a water pump~3. Complete immersion of the lesion in water~4. Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~5. Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible
Study NCT05273697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Cold Snare Polypectomy
Description: The procedure of Conventional Cold Snare Polypectomy (CCSP) will be as follows:~1. If the entry during the endoscopy has been made with water, the water will be aspirated, and the intestinal lumen will be re-stretched using air / CO2~2. Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~3. Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible
Study NCT06093854 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Description: Intraoperative radiotherapy (IORT, 15-20 Gy, 20-50min)
Study NCT06093854 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic body radiotherapy (SBRT)
Description: postoperative stereotactic body radiotherapy (SBRT, 30Gy, 5 fractions, 3 weeks)
Study NCT06064175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: Patients will receive ibuprofen 400 mg/4 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
Study NCT06064175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Description: Patients will receive ibuprofen 800 mg/8 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
Study NCT06208969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive nutrition counseling
Description: individualized regular nutrition education
Study NCT06208969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: intensive nutrition counseling
Description: individualized regular nutrition education
Study NCT06064214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: u/s guided intermediate cervical plexus block
Description: The patient will be placed in supine position,u/s probe is placed on the lateral neck, overlying the sternomastoid muscle at the level of its midpoint , Once the SCM has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.cervical plexus is visible as a small collection of hypoechoic nodules ( immediately superficial to the prevertebral fascia the needle is passed through the skin, platysma, and investing layer of the deep cervical fascia, and the tip is placed adjacent to the plexus,bupivicaine 0.25% (5-15 mL) is administered to envelop the plexus
Study NCT06064214 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: u/s guided intermediate cervical plexus block
Description: The patient will be placed in supine position,u/s probe is placed on the lateral neck, overlying the sternomastoid muscle at the level of its midpoint , Once the SCM has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.cervical plexus is visible as a small collection of hypoechoic nodules ( immediately superficial to the prevertebral fascia the needle is passed through the skin, platysma, and investing layer of the deep cervical fascia, and the tip is placed adjacent to the plexus,bupivicaine 0.25% (5-15 mL) is administered to envelop the plexus
Study NCT06158399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine in combination with R-CHOP
Description: Specified dose on specified days:~Azacitidine (A) 100mg subcutaneous d-1 to d-5 Rituximab (R) 375mg/m2 IV d0 Cyclophosphamide (C) 750mg/m2 IV d1 epirubicin (H) 75mg/m2 IV d1 or liposomal adriamycin (D) 25-30mg/m2 IV d1 Vincristine (O) 1.4mg/m2 (max 2mg) IV d1 Prednisone (P) 100mg orally d1-5
Study NCT05216549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water-based exercise
Description: 8 weeks x 2 times per week for 45 min
Study NCT05216549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Land-based exercise
Description: 8 weeks x 2 times per week for 45 min
Study NCT05087706 — intervention group
Intervention type: DRUG
Intervention: Pyrotinib
Description: Pyrotinib 400mg qd po
Study NCT05087706 — intervention group
Intervention type: DRUG
Intervention: Bicalutamide
Description: Bicalutamide was administered orally at a daily dose of 50 mg
Study NCT05087706 — intervention group
Intervention type: DRUG
Intervention: Leuprorelin
Description: Leuprorelin acetate was administered subcutaneously at a dose of 3.75 mg every 4 weeks
Study NCT04732494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab is a monoclonal antibody formulated for intravenous injection.
Study NCT04732494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tislelizumab
Description: Tislelizumab is a monoclonal antibody formulated for intravenous injection.
Study NCT04732494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Ociperlimab is a monoclonal antibody formulated for intravenous injection.
Study NCT04732494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ociperlimab placebo injection is a sterile, preservative-free solution for infusion formulated in the same buffer as ociperlimab active drug.